Pulmonary arterial hypertension

References

• Runo J. R., Loyd J. E. Primary pulmonary hypertension. Lancet 2003; 361: 1533–44
   PubMed Web of Science ®Google Scholar
• Voelkel N. F., Tuder R. M., Weir E. K. Pathophysiology of primary pulmonary hypertension. Primary pulmonary hypertension., L. J Rubin, S Rich, editors. Marcel Dekker, New York 1997; p. 83–129, In
   Google Scholar
• Simonneau G., Galie N., Rubin L. J., Langleben D., Seeger W., Domenighetti G., et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004; 43: 5S–12S
   PubMed Web of Science ®Google Scholar
• Rubin L. J. Primary pulmonary hypertension. N Engl J Med 1997; 336: 111–7
   PubMed Web of Science ®Google Scholar
• McGoon M., Gutterman D., Steen V., Barst R., McCrory D. C., Fortin T. A., et al. Screening, early detection and diagnosis of pulmonary arterial hypertension: ACCP evidence‐based clinical practice guideline. Chest 2004; 126((Suppl))14S–34S
   Google Scholar
• Gaine S. P., Rubin L. J. Primary pulmonary hypertension. Lancet 1998; 352: 719–25
   PubMed Web of Science ®Google Scholar
• Rich S., Dantzker D. R., Ayres S. M., Bergofsky E. H., Brundage B. H., Detre K. M., et al. Primary pulmonary hypertension. A national prospective study. Ann Intern Med 1987; 107: 216–23
   PubMed Web of Science ®Google Scholar
• Barst R. J. Medical therapy of pulmonary hypertension: an overview of treatment and goals. Clin Chest Med 2001; 22: 509–15
   Google Scholar
• Fishman A. P. Clinical classification of pulmonary hypertension. Clin Chest Med 2001; 22: 385–91
   Google Scholar
• Humbert M., Nunes H., Sitbon O., Parent F., Herve P., Simonneau G. Risk factors for pulmonary arterial hypertension. Clin Chest Med 2001; 22: 459–75
   PubMed Web of Science ®Google Scholar
• Pietra G. G., Capron F., Stewart S., Leone O., Humbert M., Robbins I. M., et al. Pathologic assessment of vasculopathies in pulmonary hypertension. J Am Coll Cardiol 2004; 43: 25S–32S
   PubMed Web of Science ®Google Scholar
• Pietra G. C. The pathology of primary pulmonary hypertension. Primary Pulmonary Hypertension: Lung Biology in Health and Disease., L. J Rubin, S Rich, editors. Marcel Dekker, New York, NY 1997; p. 19–61, In
   Google Scholar
• Mandel J., Mark E. J., Hales C. A. Pulmonary veno‐occlusive disease. Am J Respir Crit Care Med 2000; 162: 1964–73
   PubMedGoogle Scholar
• Langleben D., Heneghan J. M., Batten A. P., Wang N. S., Fitch N., Schlesinger R. D., et al. Familial pulmonary capillary hemangiomatosis resulting in primary pulmonary hypertension. Ann Intern Med 1988; 109: 106–9
   Google Scholar
• Jeffery T. K., Morrell N. W. Molecular and cellular basis of pulmonary vascular remodeling in pulmonary hypertension. Prog Cardiovasc Dis 2002; 45: 173–202
   PubMed Web of Science ®Google Scholar
• Christman B. W., McPherson C. D., Newman J. H., King G. A., Bernard G. R., Groves B. M., et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med 1992; 327: 70–5
   PubMed Web of Science ®Google Scholar
• Giad A., Saleh D. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med 1995; 333: 214–21
   Google Scholar
• Petkov V., Mosgoeller W., Ziesche R., Raderer M., Stiebellehner L., Vonbank K., et al. Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension. J Clin Invest 2003; 111: 1339–46
   PubMed Web of Science ®Google Scholar
• Cox C. P., Linden J., Said S. I. VIP elevates platelet cyclic AMP (cAMP) levels and inhibits in vitro platelet activation induced by platelet‐activating factor (PAF). Peptides 1984; 5: 325–8
   PubMed Web of Science ®Google Scholar
• Maruno K., Absood A., Said S. I. VIP inhibits basal and histamine‐stimulated proliferation of human airway smooth muscle cells. Am J Physiol 1995; 268: L1047–51
   PubMedGoogle Scholar
• Yanisagawa M., Kurihara H., Kimura S., Gotok A., Masaki T. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988; 332: 411–5
   PubMed Web of Science ®Google Scholar
• Hirata Y., Takagi Y., Fukuda Y., Marumo F. Endothelin is a potent mitogen for rat vascular smooth muscle cells. Artherosclerosis 1989; 78: 225–8
   PubMed Web of Science ®Google Scholar
• Fagan K. A., McMutry I. F., Rodman D. M. Role of endothelin‐1 in lung disease. Respir Res 2001; 2: 90–101
   PubMed Web of Science ®Google Scholar
• DiCarlo V. S., Chen S‐J., Meng Q. C., Durand J., Yano M., Chen Y. F., et al. ETA‐receptor antagonist prevents and reverses chronic hypoxia‐induced pulmonary hypertension in rat. Am J Physiol 1995; 269: L690–97
   PubMedGoogle Scholar
• Benigni A., Remuzzi G. Endothelin antagonists. Lancet 1999; 353: 133–8
   PubMed Web of Science ®Google Scholar
• McQuillan L. P., Leung G. K., Marsden P. A., Kostyk S. K., Kourembanas S. Hypoxia inhibits expression of eNOS via transcriptional and posttranscriptional mechanisms. Am J Physiol 1994; 267: H1921–27
   PubMed Web of Science ®Google Scholar
• Allen S. W., Chatfield B. A., Koppenhafer S. A., Schaffer M. S., Wolfe R. R., Abman S. H. Circulating immunoreactive endothelin‐1 in children with pulmonary hypertension: association with acute hypoxic pulmonary vasoreactivity. Am Rev Respir Dis 1993; 148: 519–22
   PubMed Web of Science ®Google Scholar
• Giaid A., Yanagisawa M., Langleben D., Michael R. P., Levy R., Shennib H., et al. Expression of endothelin‐1 in the lungs of patients with pulmonary hypertension. N Engl J Med 1993; 328: 1732–9
   PubMed Web of Science ®Google Scholar
• Vincent J. A., Ross R. D., Kassab J., Hsu J. M., Pinsky W. W. Relation of elevated plasma endothelin in congenital heart disease to increased pulmonary blood flow. Am J Cardiol 1993; 71: 1204–7
   PubMed Web of Science ®Google Scholar
• Lee S. L., Wang W. W., Lanzillo J. J., Fanburg B. L. Serotonin produces both hyperplasia and hypertrophy of bovine pulmonary artery smooth muscle cells in culture. Am J Physiol 1994; 266: L46–52
   Google Scholar
• Herve P., Launay J. M., Scrobohaci M. L., Brenot F., Simonneau G., Petitpretz P., et al. Increased plasma serotonin in primary pulmonary hypertension. Am J Med 1995; 99: 249–54
   PubMed Web of Science ®Google Scholar
• Tuder R. M., Cool C. D., Geraci M. W., Wang J., Abman S. H., Wright L., et al. Prostacyclin synthase expression is decreased in lungs from patients with severs pulmonary hypertension. Am J Respir Crit Care Med 1999; 159: 1925–32
   PubMed Web of Science ®Google Scholar
• Dupuis J., Jasmin J. F., Prie S., Cernacek P. Importance of local production of endothelin‐1 and of the ETB receptor in the regulation of pulmonary vascular tone. Pulm Pharmacol Ther 2000; 13: 135–40
   PubMed Web of Science ®Google Scholar
• Kuc R., Davenport A. Endothelin‐A receptors in human aorta and pulmonary arteries are downregulated in patients with cardiovascular disease: an adaptive response to increased levels of endothelin‐1?. J Cardiovasc Pharmacol 2000; 36 Suppl 1: S377–9
   Google Scholar
• Cool C. D., Stewart J. S., Werahera P., Miller G. J., Williams R. L., Voelkel N. F., et al. Three‐dimensional reconstruction of pulmonary arteries in plexiform pulmonary hypertension using cell‐specific markers. Evidence for a dynamic and heterogeneous process of pulmonary endothelial cell growth. Am J Pathol 1999; 155: 411–9
   PubMed Web of Science ®Google Scholar
• Tuder R. M., Flook B. E., Voelkel N. F. Increased gene expression for VEGF and the VEGF receptors KDR/Flk and Flt in lungs exposed to acute or chronic hypoxia: modulation of gene expression by nitric oxide. J Clin Invest 1995; 95: 1798–807
   PubMed Web of Science ®Google Scholar
• Yeager M. E., Halley G. R., Golpon H. A., Voelkel N. F., Tuder R. M. Microsatellite instability of endothelial cell growth and apoptosis genes within plexiform lesions in primary pulmonary hypertension. Circ Res 2001; 88: E2–11
   PubMed Web of Science ®Google Scholar
• Humbert M., Morrell N. W., Archer S. L., Stenmark K. R., MacLean M. R., Lang I. M., et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43: 13S–24S
   PubMed Web of Science ®Google Scholar
• Abenhaim L., Moride Y., Brenot F., Rich S., Benichou J., Kurz X., et al. Appetite‐suppressant drugs and the risk of primary pulmonary hypertension. N Engl J Med 1996; 335: 609–16
   PubMed Web of Science ®Google Scholar
• Simonneau G., Fartoukh M., Sitbon O., Humbert M., Jargot J. L., Herve P. Primary pulmonary hypertension associated with the use of fenfluramine derivatives. Chest 1998; 114((Suppl3))195S–99S
   Google Scholar
• Mark E. J., Patalas E. D., Chang H. T., Evans R. J., Kessler S. C. Fatal pulmonary hypertension associated with short‐term use of fenfluramine and phenteramine. N Engl J Med 1997; 337: 602–6
   PubMed Web of Science ®Google Scholar
• Rich S., Rubin L., Walker A. L., Schneeweiss S., Abenhaim L. Anorexigens and pulmonary hypertension in the United States: results from the Surveillance of North American Pulmonary Hypertension. Chest 2000; 117: 870–4
   PubMed Web of Science ®Google Scholar
• Albertson T. E., Walby W. F., Derlet R. W. Stimulant‐induced pulmonary toxicity. Chest 1995; 108: 1140–9
   PubMed Web of Science ®Google Scholar
• Dumas J. P., Bardou M., Goirand F., Dumas M. Hypoxic pulmonary vasoconstriction. Gen Pharmacol 1999; 33: 289–97
   PubMedGoogle Scholar
• Sweeney M., Yuan J. X. Hypoxic pulmonary vasoconstriction: role of voltage‐gated potassium channels. Respir Res 2000; 1: 40–8
   Google Scholar
• Loscalzo J. Genetic clues to the cause of primary pulmonary hypertension. N Engl J Med 2001; 345: 367–71
   Google Scholar
• Massague J., Chen Y. G. Controlling TGF‐beta signaling. Genes Dev 2000; 14: 627–44
   PubMed Web of Science ®Google Scholar
• Shi Y., Massague J. Mechanisms of TGF‐beta signaling from cell membrane nucleus. Cell 2003; 113: 685–700
   PubMed Web of Science ®Google Scholar
• Stewart D. J. Bone morphogenetic protein receptor‐2 and pulmonary arterial hypertension. Circ Res 2005; 96: 1033–5
   PubMed Web of Science ®Google Scholar
• Lane K. B., Machado R. D., Pauciulo M. W., Thomson J. R., Philips J. A., 3rd., Loyd J. E., et al. Heterozygous germ‐line mutations in BMPR2, encoding a TGF‐β receptor, cause familial primary pulmonary hypertension. Nat Genet 2000; 26: 81–4
   PubMed Web of Science ®Google Scholar
• Thomson J. R., Machado R. D., Pauciulo M. W., Morgan N. V., Humbert M., Elliot G. C., et al. Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR‐II, a receptor member of the TGF‐β family. J Med Genet 2000; 37: 741–5
   PubMed Web of Science ®Google Scholar
• Newman J. H., Wheeler L., Lane K. B., Loyd E., Gaddipati R., Philips J. A., 3rd., et al. Mutation in the gene for bone morphogenetic protein receptor II as a cause of primary pulmonary hypertension in a large kindred. N Engl J Med 2001; 345: 319–24
   PubMed Web of Science ®Google Scholar
• Newman J. H., Trembath R. C., Morse J. A., Grunig E., Loyd J. E., Adnot S., et al. Genetic basis of pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43: 33S–39S
   PubMed Web of Science ®Google Scholar
• Loyd J. E., Butler M. G., Foround T. M., Conneally P. M., Phillips J. R., Newman J. H. Genetic anticipation and abnormal gender ratio at birth in familial primary pulmonary hypertension. Am J Respir Crit Care Med 1995; 152: 93–7
   PubMed Web of Science ®Google Scholar
• Humbert M., Deng Z., Simonneau G., Barst R. J., Sitbono O., Wolf M., et al. BMPR2 germline mutations in primary pulmonary hypertension associated with fenfluramine derivatives. Eur Respir J 2002; 20: 518–23
   PubMed Web of Science ®Google Scholar
• Runo J. R., Vnencak‐Kones C. L., Prince M., Loyd J. E., Wheeler L., Robbins I. M., et al. Pulmonary veno‐occlusive disease caused by an inherited mutation in bone morphogenetic protein receptor II. Am J Respir Crit Care Med 2003; 167: 889–94
   PubMed Web of Science ®Google Scholar
• Deng Z., Morse J. H., Slager S. L., Cuervo N., Moore K. J., Venetos G., et al. Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor‐II gene. Am J Hum Genet 2000; 67: 737–44
   PubMed Web of Science ®Google Scholar
• Eddahibi S., Humbert M., Fadel E., Raffestin B., Darmon M., Capron F., et al. Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension. J Clin Invest 2001; 108: 1141–5
   PubMed Web of Science ®Google Scholar
• MacLean M. R., Herve P., Eddahibi S., Adnot S. 5‐Hydroxytryptamine and the pulmonary circulation: receptors, transporters and relevance to pulmonary arterial hypertension. Br J Pharmacol 2000; 131: 161–8
   PubMed Web of Science ®Google Scholar
• Eddahibi S., Chaouat A., Morrell N., Fadel E., Fuhrman C., Bugnet A. S., et al. Polymorphism of the serotonin transporter gene and pulmonary hypertension in chronic obstructive pulmonary disease. Circulation 2003; 108: 1839–44
   PubMed Web of Science ®Google Scholar
• Farber H. W., Loscalzo J. Pulmonary arterial hypertension. N Engl J Med 2004; 351: 1655–65
   PubMed Web of Science ®Google Scholar
• Silver R. M. Scleroderma‐clinical problems: the lungs. Rheum Dis Clin North Am 1996; 22: 825–40
   Google Scholar
• Battle R. W., Davitt M. A., Cooper S. M., Buckley L. M., Leib E. S., Beglin P. A., et al. Prevalence of pulmonary hypertension in limited and diffuse scleroderma. Chest 1996; 110: 1515–9
   PubMed Web of Science ®Google Scholar
• Peacock A. J. Primary pulmonary hypertension. Thorax 1999; 54: 1107–18
   PubMed Web of Science ®Google Scholar
• Spiech R., Jenni R., Opravil M., Pfab M., Russi E. W. Primary pulmonary hypertension in HIV infection. Chest 1991; 100: 1268–71
   Google Scholar
• Farber H. W. HIV‐associated pulmonary hypertension. AIDS Clin Care 2001; 13: 53–9
   Google Scholar
• Weiss R. A., Whitby D., Talbot S., Kellam P., Boshoff C. Human herpesvirus 8 and Kaposi's sarcoma. J Natl Cancer Inst Monogr 1998; 23: 51–4
   Google Scholar
• Cool C. D., Rai P. R., Yeager M. E., Hernandez‐Saavedra D., Serls A. E., Bull T. M., et al. Expression of human herpesvirus 8 in primary pulmonary hypertension. N Engl J Med 2003; 349: 1113–22
   PubMed Web of Science ®Google Scholar
• Yang Y. Y., Lin H. C., Lee W. C., Hou M. C., Lee F. Y., Chang F. Y., et al. Portopulmonary hypertension: distinctive hemodynamic and clinical manifestations. J Gastroenterol 2001; 36: 181–6
   PubMed Web of Science ®Google Scholar
• Donovan C. L., Marcovitz P. A., Punch J. D., Bach D. S., Brown K. A., Lucey M. R., et al. Two‐dimensional and dobutamine stress echocardiography in the preoperative assessment of patients with end‐stage liver disease prior to orthotopic liver transplantation. Transplantation 1996; 61: 1180–8
   PubMed Web of Science ®Google Scholar
• Molden D., Abraham J. L. Pulmonary hypertension: its association with hepatic cirrhosis and iron accumulation. Arch Pathol Lab Med 1982; 106: 328–31
   Google Scholar
• Castro O., Hoque M., Brown B. D. Pulmonary hypertension in sickle cell disease: cardiac catheterization results and survival. Blood 2003; 101: 1257–61
   PubMed Web of Science ®Google Scholar
• Jison M. L., Gladwin M. T. Hemolytic anemia‐associated pulmonary hypertension of sickle cell disease and the nitric oxide/arginine pathway. Am J Resp Crit Care Med 2003; 168: 3–4
   PubMed Web of Science ®Google Scholar
• Minter K. R., Gladwin M. T. Pulmonary complications of sickle cell anemia. A need for increased recognition, treatment, and research. Am J Resp Crit Care Med 2001; 164: 2016–9
   PubMed Web of Science ®Google Scholar
• Hoeper M. M., Niedermeyer J., Hoffmeyer F., Flemming P., Fabel H. Pulmonary hypertension after splenectomy?. Ann Intern Med 1999; 130: 506–9
   PubMed Web of Science ®Google Scholar
• Atichartakarn V., Likittanasombat K., Chuncharunee S., Chandanamattha P., Worapongpaiboon S., Angchaisuksiri P., et al. Pulmonary arterial hypertension in previously splenectomized patients with β‐thalassemic disorders. Int J Hematol 2003; 78: 139–45
   PubMed Web of Science ®Google Scholar
• Marvin K., Spellberg R. D. Pulmonary hypertension secondary to thrombocytosis in a patient with myeloid metaplasia. Chest 1993; 103: 642–4
   PubMed Web of Science ®Google Scholar
• Rostagno C., Prisco D., Abbate R., Poggesi L. Pulmonary hypertension associated with long‐standing thrombocytosis. Chest 1991; 99: 1303–5
   PubMed Web of Science ®Google Scholar
• Trembath R. C., Thomson J. R., Machado R. D., Morgan N. V., Atkins C., Winship I., et al. Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia. N Engl J Med 2001; 345: 325–34
   PubMed Web of Science ®Google Scholar
• Chaouat A., Coulet F., Favre C., Simonneau G., Weitzenblum E., Soubrier F., et al. Endoglin germline mutation in a patient with hereditary haemorrhagic telangiectasia and dexfenfluramine associated pulmonary arterial hypertension. Thorax 2004; 59: 446–8
   PubMed Web of Science ®Google Scholar
• Barst R. J., McGoon M., Torbicki A., Sitbon O., Krowka M. J., Olschewski H., et al. Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43: 40S–47S
   PubMed Web of Science ®Google Scholar
• Bossone E., Avelar E., Bach D. S., Gillespie B., Rubenfire M., Armstrong W. F. Diagnostic value of resting tricuspid regurgitation velocity and right ventricular ejection flow parameters for the detection of exercise‐induced pulmonary arterial hypertension. Int J Card Imaging 2000; 16: 429–36
   Google Scholar
• Ommen S. R., Nishimura R. A., Hurrell D. G., Klarich K. W. Assessment of right atrial pressure with 2‐dimensional and Doppler echocardiography: a simultaneous catheterization and echocardiographic study. Mayo Clin Proc 2000; 75: 24–9
   PubMed Web of Science ®Google Scholar
• Denton C., Cailes J., Phillips G., Wells A., Black C., Du Bois R. Comparison of Doppler echocardiography and right heart catheterization to assess pulmonary hypertension in systemic sclerosis. Br J Rheumatol 1997; 36: 239–43
   PubMedGoogle Scholar
• Penning S., Robinson K., Major C., Garite T. A comparison of echocardiography and pulmonary artery catheterization for evaluation of pulmonary artery pressures in pregnant patients with suspected pulmonary hypertension. Am J Obstet Gynecol 2001; 184: 1568–70
   Google Scholar
• Rich S., Kieras K., Hart K., Groves B. M., Stobo J. D., Brundage B. H. Antinuclear antibodies in primary pulmonary hypertension. J Am Coll Cardiol 1986; 8: 1307–11
   PubMed Web of Science ®Google Scholar
• Morris T. A., Auger W. R., Ysrael M. Z., Olson L. K., Channick R. N., Fedullo P. F., et al. Parenchymal scarring is associated with restrictive spirometric defects in patients with chronic thromboembolic pulmonary hypertension. Chest 1996; 110: 399–403
   Google Scholar
• Owens G. R., Fino G. J., Herbert D. L., Steen V. D., Medsger T. A., Jr., Pennock B. E., et al. Pulmonary function in systemic sclerosis. Comparison of CREST syndrome variant with diffuse scleroderma. Chest 1983; 84: 546–50
   Google Scholar
• Steen V., Medsger T. A., Jr. Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. Arthritis Rheum 2003; 48: 516–22
   PubMed Web of Science ®Google Scholar
• Rafanan A. L., Golish J. A., Dinner D. S., Hague L. K., Arroliga A. C. Nocturnal hypoxemia is common in primary pulmonary hypertension. Chest 2001; 120: 849–9
   Google Scholar
• Atwood C. W., Jr., McCrory D., Garcia J. G., Abman S. H., Ahearn G. S. Pulmonary artery hypertension and sleep‐disordered breathing: ACCP evidence‐based clinical practice guidelines. Chest 2004; 126: 72S–7S
   Web of Science ®Google Scholar
• Fedullo P. F., Auger W. R., Kerr K. M., Rubin L. J. Chronic thromboembolic pulmonary hypertension. N Engl J Med 2001; 345: 1465–72
   PubMed Web of Science ®Google Scholar
• Azarian R., Wartski M., Collignon M. A., Parent F., Herve P., Sors H., et al. Lung perfusion scans and hemodynamics in acute and chronic pulmonary embolism. J Nuc Med 1997; 38: 980–3
   PubMed Web of Science ®Google Scholar
• Worsley D. F., Palevsky H. I., Alavi A. Ventilation‐perfusion lung scanning in the evaluation of pulmonary hypertension. J Nucl Med 1994; 35: 793–6
   PubMed Web of Science ®Google Scholar
• D'Alonzo G. E., Bower J. S., Dantzker D. R. Differentiation of patients with pulmonary and thromboembolic pulmonary hypertension. Chest 1984; 85: 457–61
   PubMed Web of Science ®Google Scholar
• Moser K. M., Auger W. R., Fedullo P. F. Chronic major‐vessel thromboembolic pulmonary hypertension. Circulation 1990; 81: 1735–43
   PubMed Web of Science ®Google Scholar
• Pruszczyk P., Torbicki A., Pacho R., Chellum M., Kuch‐Wocial A., Pusznski B., et al. Noninvasive diagnosis of suspected severe pulmonary embolism: transesophageal echocardiography vs. spiral CT. Chest 1997; 112: 722–8
   Web of Science ®Google Scholar
• Jamieson S. W., Kapelanski D. P., Sakakibara N., Manecke G. R., Thistlethwaite P. A., Kerr K. M., et al. Pulmonary thromboendartectomy. Experience and results in 1,500 cases. Ann Thorac Surg 2003; 76: 1457–64
   PubMed Web of Science ®Google Scholar
• Miyamoto S., Nagaya N., Satoh T., Kyotani S., Sakamaki F., Fujita M., et al. Clinical correlates and prognostic significance of six‐minute walk test in patients with primary pulmonary hypertension: comparison with cardiopulmonary exercise testing. Am J Respir Crit Care Med 2000; 161: 487–92
   PubMed Web of Science ®Google Scholar
• Rubin L. J., Badesch D. B. Evaluation and management of the patient with pulmonary arterial hypertension. Ann Intern Med 2005; 143: 282–93
   PubMed Web of Science ®Google Scholar
• Paciocco G., Martinez F., Bossone E., Pielsticker E., Gillespie B., Rubenfire M. Oxygen desaturation on the six‐minute walk test and mortality in untreated primary pulmonary hypertension. Eur Respir J 2001; 17: 647–52
   PubMed Web of Science ®Google Scholar
• Hoeper M. M., Oudiz R. J., Peacock A., Tapson V. F., Haworth S. G., Frost A. E., et al. End points and clinical trial designs in pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43: 48S–55S
   PubMed Web of Science ®Google Scholar
• Humbert M., Sitbon O., Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 2004; 351: 1425–36
   PubMed Web of Science ®Google Scholar
• Fuster V., Steele P. M., Edwards W. D., Gersh B. J., McGoon M. D., Frye R. L. Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation 1984; 70: 580–7
   PubMed Web of Science ®Google Scholar
• Rich S., Kaufmann E., Levy P. S. The effect of high doses of calcium‐channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992; 327: 76–81
   PubMed Web of Science ®Google Scholar
• Rich S., Brundage B. H. High‐dose calcium channel‐blocking therapy for primary pulmonary hypertension: evidence for long‐term reduction in pulmonary arterial pressure and regression of right ventricular hypertrophy. Circulation 1987; 76: 135–41
   PubMed Web of Science ®Google Scholar
• Raffy O., Azarian R., Brenot F., Parent F., Sitbon O., Petitpretz P., et al. Clinical significance of the pulmonary vasodilator response during short‐term infusion of prostacyclin in primary pulmonary hypertension. Circulation 1996; 93: 484–8
   PubMed Web of Science ®Google Scholar
• Barst R. J., Maislin G., Fishman A. P. Vasodilator therapy for primary pulmonary hypertension in children. Circulation 1999; 99: 1197–208
   PubMed Web of Science ®Google Scholar
• Nootens M., Kaufmann E., Rich S. Short‐term effectiveness of nifedipine in secondary pulmonary hypertension. Am J Cardiol 1993; 71: 1475–6
   Google Scholar
• Rubin L. J., Mendoza J., Hood M., McGoon M., Barst R., Williams W. B., et al. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial. Ann Intern Med 1990; 112: 485–91
   PubMed Web of Science ®Google Scholar
• Barst R. J., Rubin L. J., Long W. A., McGoon M. D., Rich S., Badesch D. B., et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 1996; 334: 296–302
   PubMed Web of Science ®Google Scholar
• Badesch D. B., Tapson V. F., McGoon M. D., Brundage B. H., Rubin L. J., Wigley F. M., et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med 2000; 132: 425–34
   PubMed Web of Science ®Google Scholar
• Stibon O., Humbert M., Nunes H., Parent F., Garcia G., Herve P., et al. Long‐term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 2002; 40: 780–8
   Google Scholar
• Barst R. J., Rubin L. J., McGoon M. D., Caldwell E. J., Long W. A., Levy P. S. Survival in primary pulmonary hypertension with long‐term continuous intravenous prostacyclin. Ann Intern Med 1994; 121: 409–15
   PubMed Web of Science ®Google Scholar
• Shapiro S. M., Oudiz R. J., Cao T., Romano M. A., Beckmann X. J., Georgiou D., et al. Primary pulmonary hypertension: improved long‐term effects and survival with continuous intravenous epoprostenol infusion. J Am Coll Cardiol 1997; 30: 343–9
   PubMed Web of Science ®Google Scholar
• McLaughlin V. V., Shillington A., Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 2002; 106: 1477–82
   PubMed Web of Science ®Google Scholar
• Rosenzweig E. B., Kerstein D., Barst R. J. Long‐term prostacyclin for pulmonary hypertension with associated congenital heart defects. Circulation 1999; 99: 1858–65
   PubMed Web of Science ®Google Scholar
• Kuo P. C., Johnson L. B., Plotkin J. S., Howell C. D., Bartlett S. T., Rubin L. J. Continuous intravenous infusion of epoprostenol for the treatment of portopulmonary hypertension. Transplantation 1997; 63: 604–6
   PubMed Web of Science ®Google Scholar
• Aquilar R. V., Farber H. W. Epoprostenol (prostacyclin) therapy in HIV‐associated pulmonary hypertension. Am J Respir Crit Care Med 2000; 162: 1846–50
   Google Scholar
• Simonneau G., Barst R. J., Galie N., Naeije R., Rich S., Bourge R. C., et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double‐blind randomized, placebo‐controlled trial. Am J Respir Crit Care Med 2002; 165: 800–4
   PubMed Web of Science ®Google Scholar
• Galie N., Humbert M., Vachiery J. L., Vizza C. D., Kneussel M., Manes A., et al. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double‐blind, placebo‐controlled trial. J Am Coll Cardiol 2002; 39: 1496–502
   PubMed Web of Science ®Google Scholar
• Barst R. J., McGoon M., McLauglin V., Tapson V., Rich S., Rubin L., et al. Baraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2003; 41: 2119–25
   PubMed Web of Science ®Google Scholar
• Oleschewski H., Ghofrani H. A., Schmehl T., Winkleer J., Wilkens H., Hoper M. M., et al. Inhaled iloprost to treat severe pulmonary hypertension. An uncontrolled trial. German PPH Study Group. Ann Intern Med 2000; 132: 435–43
   Google Scholar
• Hoeper M. M., Schwarze M., Ehlerding S., Adler‐Schuermeyer A., Spiekerkoetter E., Niedermeyer J., et al. Long‐term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. N Engl J Med 2000; 342: 1866–70
   PubMed Web of Science ®Google Scholar
• Oleschewski H., Simonneau G., Galie N., Higenbottam T., Naeije R., Rubin L. J., et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002; 347: 322–9
   Google Scholar
• Channick R. N., Simonneau G., Sitbon O., Robbins I. M., Frost A., Tapson V. F., et al. Effects of the dual endothelin‐receptor antagonist bosentan in patients with pulmonary hypertension: a randomized placebo‐controlled study. Lancet 2001; 358: 1119–23
   PubMed Web of Science ®Google Scholar
• Rubin L. J., Badesch D. B., Barst R. J., Galie N., Black C. M., Keogh A., et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 346: 896–903
   PubMed Web of Science ®Google Scholar
• Barst R. J., Langleben D., Frost A., Horn E. M., Oudiz R., Shapiro S., et al. Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med 2004; 169: 441–7
   PubMed Web of Science ®Google Scholar
• Beavo J. A., Reifsynder D. H. Primary sequence of cyclic nucleotide phosphodiesterase isozymes and the design of selective inhibitors. Trends Pharmacol Sci 1990; 11: 150–5
   PubMed Web of Science ®Google Scholar
• Ahn H. S., Foster M., Cable M., Pitts B. J., Sybertz E. J. Ca/CaM‐stimulated and cGMP‐specific phosphodiesterases in vascular and non‐vascular tissues. Adv Exp Med Biol 1991; 308: 191–7
   PubMedGoogle Scholar
• Braner D. A., Fineman J. R., Chang R., Soifer S. J. M&B 22948, a cGMP phosphodiesterase inhibitor is a pulmonary vasodilator in lambs. Am J Physiol 1993; 264: H252–8
   Google Scholar
• Michalakis E., Tymchak W., Lien D., Webster L., Hashimoto K., Archer S. Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide. Circulation 2002; 105: 2398–403
   Google Scholar
• Lepore J. J., Maroo A., Pereira N. L., Ginns L. C., Dec G. W., Zapol W. M., et al. Effect of sildenafil on the acute pulmonary vasodilator response to inhaled nitric oxide in adults with primary pulmonary hypertension. Am J Cardiol 2002; 90: 677–80
   PubMed Web of Science ®Google Scholar
• Wilkens H., Guth A., Konig J., Forestier N., Cremers B., Hermen B., et al. Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. Circulation 2001; 104: 1218–22
   PubMed Web of Science ®Google Scholar
• Rothman A., Slansky M. S., Lucas V. W., Kashanie I. A., Shughneny R. D., Channick R. H. Atrial septostomy as a bridge to lung transplantation in patients with severe pulmonary hypertension. Am J Cardiol 1999; 84: 682–6
   PubMed Web of Science ®Google Scholar
• Sandoval J., Rothman A., Pulido T. Atrial septostomy for pulmonary hypertension. Clin Chest Med 2001; 22: 547–60
   PubMed Web of Science ®Google Scholar
• Sandoval J., Gaspar J., Pulido, Bautista E., Martinez‐Guerra M. L., Zeballos M., et al. Graded balloon dilation atrial septostomy in severe primary pulmonary hypertension. A therapeutic alternative for patients non‐responsive to vasodilator treatment. J Am Coll Cardiol 1998; 32: 297–304
   PubMed Web of Science ®Google Scholar
• Jamieson S. W., Auger W. R., Fedullo P. F., Channick R. N., Kirett J. M., Tarazi R. Y., et al. Experience and results with 150 pulmonary thromboendarterectomy operations over a 29‐month period. J Thorac Cardiovasc Surg 1993; 106: 116–27
   PubMed Web of Science ®Google Scholar
• Archibald C. J., Auger W. R., Fedullo P. F., Channick R. N., Kerr K. M., Jamieson S. W., et al. Long‐term outcome after pulmonary thromboendartectomy. Am J Respir Crit Care Med 1999; 160: 523–8
   PubMed Web of Science ®Google Scholar
• Wensel R., Opitz C. F., Anker S. D., Winkler J., Hoffken G., Kleber F. X., et al. Assessment of survival in patients with primary pulmonary hypertension. Importance of cardiopulmonary exercise testing. Circulation 2002; 106: 319–24
   PubMed Web of Science ®Google Scholar
• Doyle R. l., McCrory D., Channick R. N., Simmonneau G., Conte J. Surgical treatments/interventions for pulmonary arterial hypertension: ACCP evidence‐based clinical practice guidelines. Chest 2004; 126: 63S–71S
   PubMed Web of Science ®Google Scholar
• Pielsticker E. J., Martinez F. J., Rubenfire M. Lung and heart‐lung transplant practice patterns in pulmonary hypertension centers. J Heart Lung Transplant 2001; 20: 1297–304
   Google Scholar
• Boujoukos A. J., Martich G. D., Vega J. D., Keenan R. J., Griffith B. P. Reperfusion injury in single lung transplant recipients with pulmonary hypertension and emphysema. J Heart Lung Transplant 1997; 16: 440–48
   Google Scholar
• Hertz M. I., Mohacsi P. J., Taylor D. O., Trulock E. P., Boucek M. M., Deng M. C., et al. The registry of the International Society for Heart and Lung Transplantation: twentieth official report. J Heart Lung Transplant 2003; 22: 610–15
   Google Scholar
• Whyte R. I., Robbins R. C., Altinger J., Barlow C. W., Doyle R. L., Theodore J., et al. Heart‐lung transplantation for primary pulmonary hypertension. Ann Thorac Surg 1999; 67: 937–41
   Google Scholar
• Bando K., Armitage J. M., Paradis I. L., Keenan R. J., Hardesty R. L., Konishi H., et al. Indications for and results of single, bilateral, and heart‐lung transplantation for pulmonary hypertension. J Thorac Cardiovasc Surg 1994; 108: 1056–65
   PubMed Web of Science ®Google Scholar
• Klepetko W., Mayer E., Sandoval J., Trulock E., Vachiery J. L., Dartevelle P., et al. Interventional and surgical modalities of treatment for pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43: 73S–80S
   PubMed Web of Science ®Google Scholar
• Sharples L. D., Tamm M., McNeil K., Higenbottam T. W., Stewart S., Wallwork J. Development of bronchiolitis obliterans syndrome in recipients of heart‐lung transplantation: early risk factors. Transplantation 1996; 61: 560–6
   PubMedGoogle Scholar
• Galie N., Seeger W., Naeije R., Simonneau G., Rubin L. J. Comparative analysis of clinical trials and evidence‐based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43: 81S–88S
   PubMed Web of Science ®Google Scholar